March 9, 2007 – Amgen hit another 52-week low following news the FDA will require boxed warnings on its anemia drugs, Aranesp and Epogen; Liponex lost almost 80% of its value after its treatment for HDL cholesterol failed a trial; Jazz Pharma registered with the SEC to raise $172.5 million in its IPO; and the auditors for Encysive placed a going concern warning on their report for Encysive. The Centient Biotech 200™ slipped 4 points lower to 3822, a loss of .10%. More details...
